Trial
NCT00953706
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Vertex Pharmaceuticals Incorporated
Collaborators
Cystic Fibrosis Foundation
Condition
Cystic Fibrosis
Intervention
Ivacaftor
Why stopped
Following review of results obtained from a pre-specified 6-month analysis of Part B data the study was terminated on the basis of futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-09-11